Payment overview · 2025
General Payments
$1,111.91
64 reported records · 17 companies
Healthcare provider profile · identity verified
Korhan B Raif, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BARRY, IL · NPI 1184697476
Verified facts
What the public records show
CMS Open Payments records show Korhan B Raif, MD received $1,111.91 in general payments during 2025 across 64 reported records.
Novo Nordisk Inc accounted for 20.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Jardiance, Mounjaro, Ozempic, Rexulti, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 398 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 180 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 184 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 398 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $228.73 | 20.6% | 14 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $215.71 | 19.4% | 14 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $70.62 | 6.3% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $66.32 | 6.0% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $64.66 | 5.8% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $61.10 | 5.5% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $57.87 | 5.2% | 4 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $57.72 | 5.2% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $51.11 | 4.6% | 3 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $50.45 | 4.5% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $45.87 | 4.1% | 3 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $32.49 | 2.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $30.82 | 2.8% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $19.98 | 1.8% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $19.86 | 1.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.48 | 1.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.12 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,111.91 | 64 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $180.21 | 10 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $96.98 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $96.95 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $82.39 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $80.22 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $66.32 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $57.87 | 4 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $57.72 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $53.28 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $53.04 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $51.11 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $50.59 | 3 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $50.45 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $48.52 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $48.27 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $47.92 | 3 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $32.49 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $30.82 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $20.03 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $19.98 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $19.86 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $19.48 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.48 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.39 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 25 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 398 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 184 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 91 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 56 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 77 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
62 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
398 | 68 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
25 | 25 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
77 | 15 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
180 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
184 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
100 | 16 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
91 | 21 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
398 | 68 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
27 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 824 | 208 |
| Levothyroxine Sodium | Levothyroxine Sodium | 628 | 156 |
| Amlodipine Besylate | Amlodipine Besylate | 573 | 149 |
| Furosemide | Furosemide | 568 | 109 |
| Potassium Chloride | Potassium Chloride | 557 | 138 |
| Lisinopril | Lisinopril | 524 | 127 |
| Pantoprazole Sodium | Pantoprazole Sodium | 460 | 116 |
| Duloxetine Hcl | Duloxetine Hcl | 440 | 82 |
| Metoprolol Succinate | Metoprolol Succinate | 422 | 109 |
| Eliquis | Apixaban | 398 | 68 |
| Gabapentin | Gabapentin | 360 | 78 |
| Omeprazole | Omeprazole | 345 | 92 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 324 | 67 |
| Losartan Potassium | Losartan Potassium | 301 | 75 |
| Simvastatin | Simvastatin | 301 | 84 |
| Metformin Hcl | Metformin Hcl | 295 | 71 |
| Allopurinol | Allopurinol | 288 | 77 |
| Escitalopram Oxalate | Escitalopram Oxalate | 277 | 50 |
| Ropinirole Hcl | Ropinirole Hcl | 271 | 46 |
| Montelukast Sodium | Montelukast Sodium | 267 | 67 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 259 | 77 |
| Metoprolol Tartrate | Metoprolol Tartrate | 259 | 50 |
| Prednisone | Prednisone | 234 | 45 |
| Metformin Hcl Er | Metformin Hcl | 226 | 58 |
| Donepezil Hcl | Donepezil Hcl | 225 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 222 | 63 |
| Tramadol Hcl | Tramadol Hcl | 205 | 61 |
| Tamsulosin Hcl | Tamsulosin Hcl | 198 | 51 |
| Famotidine | Famotidine | 190 | 43 |
| Glimepiride | Glimepiride | 184 | 40 |
| Jardiance | Empagliflozin | 184 | 29 |
| Xarelto | Rivaroxaban | 180 | 20 |
| Alprazolam | Alprazolam | 178 | 37 |
| Sertraline Hcl | Sertraline Hcl | 178 | 36 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 177 | 54 |
| Clopidogrel | Clopidogrel Bisulfate | 176 | 42 |
| Celecoxib | Celecoxib | 173 | 42 |
| Trazodone Hcl | Trazodone Hcl | 170 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 169 | 51 |
| Fluticasone Propionate | Fluticasone Propionate | 167 | 58 |
| Pregabalin | Pregabalin | 166 | 32 |
| Spironolactone | Spironolactone | 153 | 36 |
| Lorazepam | Lorazepam | 150 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 138 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 135 | 68 |
| Pioglitazone Hcl | Pioglitazone Hcl | 133 | 23 |
| Bupropion Xl | Bupropion Hcl | 128 | 29 |
| Carvedilol | Carvedilol | 119 | 25 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 114 | 25 |
| Ezetimibe | Ezetimibe | 112 | 33 |
| Alendronate Sodium | Alendronate Sodium | 111 | 29 |
| Cephalexin | Cephalexin | 107 | 68 |
| Fluoxetine Hcl | Fluoxetine Hcl | 106 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 105 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 100 | 49 |
| Trulicity | Dulaglutide | 100 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 96 | 17 |
| Levetiracetam | Levetiracetam | 95 | 13 |
| Meloxicam | Meloxicam | 95 | 36 |
| Ozempic | Semaglutide | 91 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 90 | 33 |
| Diclofenac Sodium | Diclofenac Sodium | 89 | 27 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 89 | 12 |
| Warfarin Sodium | Warfarin Sodium | 86 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 85 | 20 |
| Memantine Hcl | Memantine Hcl | 85 | 15 |
| Nystatin | Nystatin | 82 | 42 |
| Mirtazapine | Mirtazapine | 81 | 16 |
| Dexamethasone | Dexamethasone | 79 | 62 |
| Levofloxacin | Levofloxacin | 79 | 66 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 77 | 15 |
| Fenofibrate | Fenofibrate | 72 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 71 | 15 |
| Buspirone Hcl | Buspirone Hcl | 71 | 24 |
| Dicyclomine Hcl | Dicyclomine Hcl | 69 | 25 |
| Topiramate | Topiramate | 69 | 12 |
| Nortriptyline Hcl | Nortriptyline Hcl | 68 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 67 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 66 | 21 |
| Methylprednisolone | Methylprednisolone | 65 | 55 |
| Finasteride | Finasteride | 64 | 21 |
| Azithromycin | Azithromycin | 62 | 55 |
| Farxiga | Dapagliflozin Propanediol | 62 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 62 | 24 |
| Chlorthalidone | Chlorthalidone | 61 | 21 |
| Propranolol Hcl Er | Propranolol Hcl | 61 | 18 |
| Naproxen | Naproxen | 60 | 14 |
| Benazepril Hcl | Benazepril Hcl | 59 | 16 |
| Rexulti | Brexpiprazole | 56 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 54 | 15 |
| Meclizine Hcl | Meclizine Hcl | 54 | 23 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 54 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 53 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 52 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 52 | 42 |
| Myrbetriq | Mirabegron | 52 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 50 | 42 |
| Albuterol Sulfate | Albuterol Sulfate | 48 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 48 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 48 | 18 |
| Januvia | Sitagliptin Phosphate | 47 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 47 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 45 | 11 |
| Digoxin | Digoxin | 45 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 44 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 42 | suppressed |
| Lovastatin | Lovastatin | 42 | 13 |
| Nifedipine Er | Nifedipine | 42 | 12 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 42 | 15 |
| Amiloride Hcl | Amiloride Hcl | 41 | suppressed |
| Baclofen | Baclofen | 41 | 11 |
| Divalproex Sodium | Divalproex Sodium | 41 | suppressed |
| Ondansetron Odt | Ondansetron | 41 | 20 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 41 | suppressed |
| Estradiol | Estradiol | 40 | suppressed |
| Ramipril | Ramipril | 40 | 13 |
| Valsartan | Valsartan | 40 | suppressed |
| Atenolol | Atenolol | 39 | 12 |
| Humalog Kwikpen U-100 | Insulin Lispro | 39 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 39 | 17 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 38 | 16 |
| Enalapril Maleate | Enalapril Maleate | 38 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 36 | 13 |
| Fluconazole | Fluconazole | 36 | 30 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 35 | suppressed |
| Nadolol | Nadolol | 35 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 35 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 32 | 24 |
| Clonazepam | Clonazepam | 32 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 31 | suppressed |
| Entresto | Sacubitril/Valsartan | 30 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 30 | 14 |
| Latanoprost | Latanoprost | 30 | suppressed |
| Methotrexate | Methotrexate Sodium | 30 | suppressed |
| Torsemide | Torsemide | 30 | suppressed |
| Gemfibrozil | Gemfibrozil | 29 | suppressed |
| Hydrocortisone | Hydrocortisone | 29 | 16 |
| Glipizide Er | Glipizide | 28 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Indomethacin | Indomethacin | 27 | suppressed |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 27 | 27 |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 26 | suppressed |
| Ibuprofen | Ibuprofen | 26 | suppressed |
| Temazepam | Temazepam | 26 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 25 | 25 |
| Diazepam | Diazepam | 23 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 19 |
| Lamotrigine | Lamotrigine | 23 | suppressed |
| Olanzapine | Olanzapine | 23 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Cefdinir | Cefdinir | 22 | 15 |
| Methocarbamol | Methocarbamol | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | 20 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 17 |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 21 | suppressed |
| Dulera | Mometasone/Formoterol | 21 | suppressed |
| Klor-Con M20 | Potassium Chloride | 21 | 15 |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 19 | suppressed |
| Fentanyl | Fentanyl | 19 | suppressed |
| Methimazole | Methimazole | 19 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Klor-Con 10 | Potassium Chloride | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 13 |
| Primidone | Primidone | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Timolol Maleate | Timolol Maleate | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 14 | suppressed |
| Briviact | Brivaracetam | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Glucagon Emergency Kit | Glucagon | 13 | suppressed |
| Lacosamide | Lacosamide | 13 | suppressed |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Norethindrone Acetate | Norethindrone Acetate | 12 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 12 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 12 | suppressed |
| Prevacid | Lansoprazole | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Paliperidone Er | Paliperidone | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,111.91 · 64 records | Novo Nordisk Inc | AIRSUPRA, AREXVY, BREZTRI, Cologuard Collection Kit, ELIQUIS, EVENITY, INGREZZA, JARDIANCE, KISUNLA, LEQVIO, MOUNJARO, NURTEC ODT, Ohtuvayre, Ozempic, REPATHA, REXULTI, Rybelsus, SPRAVATO, TRELEGY ELLIPTA, VOQUEZNA, WATCHMAN Access System, Wegovy, ZEPBOUND, ZORYVE | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error